SELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?
SELLAS Life Sciences to Participate in Upcoming Investor Conferences
SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event
Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet
All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy
Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up on Earnings Beat
SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths
SELLAS Life Sciences Group (NASDAQ:SLS) & Dianthus Therapeutics (NASDAQ:DNTH) Critical Survey
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
What's Going With SELLAS Life Sciences Stock On Wednesday?
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)
Solaris Resources (TSE:SLS) Reaches New 52-Week High – Should You Buy?
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up – What’s Next?
SELLAS Life Sciences Stock Is Surging Higher: What's Going On?
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Stock Traders Purchase High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)
SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
BlackRock just bought this stock with full voting control
Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification
SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)
SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?
SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML
Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia
SELLAS Announces Key Business Objectives for 2025
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia